8:11 AM ET
8-K
Business Update
Fate Therapeutics Business Update
Fate Therapeutics was awarded a $15 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to support its Phase 2 RECLAIM-LN clinical trial. The funding will advance the development of FT819, an off-the-shelf CAR T-cell therapy for patients with refractory lupus nephritis, a severe manifestation of systemic lupus erythematosus.
- Counterparty
- California Institute for Regenerative Medicine (CIRM)